granting Complainant's unopposed motions to terminate the investigation as to respondents Eurbus, Sunyoka123, and SeLucky based on settlement. *See* Order Nos. 5, 6, and 7 (March 11, 2025), *unreviewed by* Comm'n Notice (April 1, 2025).

On February 6, 2025, Complainant filed an unopposed motion to terminate Tigaman from the investigation based on settlement. On February 18, 2025, OUII filed a response in support of Complainant's motion. On March 11, 2025, the ALJ issued Order No. 8, requesting clarification regarding slight differences in Tigaman's name and address in the Complaint and Notice of Investigation and the settlement agreement attached to the motion to terminate. Complainant filed a response with additional information on March 18, 2025. OUII filed a response again supporting termination on March 27, 2025.

On March 18, 2025, Complainant filed an unopposed motion to terminate Junyxin from the investigation based on settlement. On March 27, 2025, OUII filed a response in support of Complainant's motion.

On April 1, 2025, the ALJ issued the subject IDs (Order Nos. 10 and 11), granting Complainant's unopposed motions to terminate the investigation as to Tigaman and Junyxin. Order No. 11 also amends the Notice of Investigation to correctly identify the address of Respondent Junyxin as: Room 205, No. 183 Dongshanli, Dong'an Jimei District, Xiamen City, China. The subject IDs find that the motions meet the requirements of Commission Rules 210.21(b) and 210.50(b)(2) (19 CFR 210.21(b), 210.50(b)(2)), and that there are no extraordinary circumstances that would prevent the requested partial termination of the investigation. The subject IDs also grant Complainant's unopposed request to limit service of he unredacted versions of the settlement agreements. No petitions for review of the IDs were filed.

The Commission has determined not to review the subject IDs. The Notice of Investigation is amended to correctly identify the address of Respondent Junyxin as: Room 205, No. 183 Dongshanli, Dong'an Jimei District, Xiamen City, China. Tigaman and Junyxin are terminated from the investigation.

The Commission vote for this determination took place on April 21, 2025.

The authority for the Commission's determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in Part 210 of the Commission's Rules of Practice and Procedure (19 CFR part 210).

By order of the Commission.

Issued: April 22, 2025.

Lisa Barton,

Secretary to the Commission.

[FR Doc. 2025–07232 Filed 4–25–25; 8:45 am]

BILLING CODE 7020–02–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–1535]

Importer of Controlled Substances Application: Skalar Pharma LLC

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

SUMMARY: Skalar Pharma LLC has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to **SUPPLEMENTARY INFORMATION** listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before May 28, 2025. Such persons may also file a written request for a hearing on the application on or before May 28, 2025.

ADDRESSES: The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to *https://www.regulations.gov* and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on *https://www.regulations.gov*. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment. All requests for a hearing must be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this is notice that on February 26, 2025, Skalar Pharma LLC, SR 53 KM 82 Guayama, Guayama, Puerto Rico 00785, applied to be registered as an importer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Phenylacetone	8501	II

The company plans to import the listed controlled substance to be used in the manufacturing process for other controlled substances. No other activity for this drug code is authorized for this registration.

Approval of permit applications will occur only when the registrant's business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale.

Matthew Strait,

Deputy Assistant Administrator.

[FR Doc. 2025–07278 Filed 4–25–25; 8:45 am]

BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–1533]

Importer of Controlled Substances Application: Lipomed

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

SUMMARY: Lipomed has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before May 28, 2025. Such persons may also file a written request for a hearing on the application on or before May 28, 2025.

ADDRESSES: The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal,